Cáncer de próstata: ¿por qué su mortalidad no está disminuyendo?

Autores/as

  • Iván Delgado-Enciso Secretaría de Salud, Instituto Estatal de Cancerología de Colima, Colima, México.Secretaría de Salud, Instituto Estatal de Cancerología de Colima, Colima, México. https://orcid.org/0000-0001-9848-862X
  • José Guzmán-Esquivel Instituto Mexicano del Seguro Social, Unidad de Investigaciones en Epidemiología Clínica, Colima, México. Instituto Mexicano del Seguro Social, Unidad de Investigaciones en Epidemiología Clínica, Colima, México. https://orcid.org/0000-0002-6727-0051

DOI:

https://doi.org/10.48193/pkxgct57

Palabras clave:

Cáncer de próstata, incidencia, mortalidad

Referencias

Guzman-Esquivel J, Murillo-Zamora E, Ortiz-Mesina M, Galvan-Salazar HR, De-Leon-Zaragoza L, Casarez-Price JC, et al. Regional and national burden of prostate cancer: incidence, mortality, years of life lost, and disability-adjusted life years, in Mexico and Latin America from 1990 to 2019. International Urology and Nephrology. 2023;55(9): 2155–2160. https://doi.org/10.1007/s11255-023-03653-7

Naghavi M, Ong KL, Aali A, Ababneh HS, Abate YH, Abbafati C, et al. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet. 2024;403(10440): 2100–2132. https://doi.org/10.1016/S0140-6736(24)00367-2.

Wang L, Lu B, He M, Wang Y, Wang Z, Du L. Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019. Frontiers in Public Health. 2022;10: 811044. https://doi.org/10.3389/fpubh.2022.811044.

Guzman Esquivel J, Mendoza Hernandez MA, Tiburcio Jimenez D, Avila Zamora ON, Delgado Enciso J, De Leon Zaragoza L, et al. Decreased biochemical progression in patients with castration resistant prostate cancer using a novel mefenamic acid anti inflammatory therapy: A randomized controlled trial. Oncology Letters. 2020;19(6): 4151–4160. https://doi.org/10.3892/ol.2020.11509.

Rojas-Martínez A, Manzanera AG, Sukin SW, Esteban-María J, González-Guerrero JF, Gomez-Guerra L, et al. Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer. Cancer Gene Therapy. 2013;20(11): 642–649. https://doi.org/10.1038/cgt.2013.56.

Ouellet V, Erickson A, on behalf of GAP1 UTMAs Contributing Investigators, Wiley K, Morrissey C, Berge V, et al. The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource. Cancer Epidemiology, Biomarkers & Prevention. 2022;31(4): 715–727. https://doi.org/10.1158/1055-9965.EPI-21-0600.

Descargas

Publicado

2024-06-28

Número

Sección

Editorial